Treats acne vulgaris. ANDA 65049, held by Padagis US. Clindamycin Phosphate.
As of Nov 15, 2026, ANDA 65049 (Clindamycin Phosphate), held by Padagis US, was first approved by FDA on May 25, 2000, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clindacin
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2000 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin PhosphateEQ 1% BASE · swab;topical | Clindamycin Phosphate | Rx |
| Apr 3, 2020 | Supplement 23Labeling · Standard review | Approved | None posted |
| Apr 3, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 15, 2015 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 14, 2014 | Supplement 11Labeling | Approved | None posted |
| Oct 19, 2010 | Supplement 10Labeling | Approved | None posted |
| Nov 30, 2009 | Supplement 9Labeling | Approved | None posted |
| Jun 27, 2002 | Supplement 5Labeling | Approved | None posted |
| Jun 27, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Nov 21, 2001 | Supplement 3Labeling | Approved | None posted |
| Nov 21, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Nov 21, 2001 | Supplement 1Manufacturing | Approved | None posted |
| May 25, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters